Johnson & Johnson

JNJNYSE

Market cap649.4B USDAs of Sep 22, 2026

Healthcare· Drug Manufacturers - General· US

$269.47

Session change unavailable

Market closed · NYSE

Status checked Oct 24, 2026, 6:52 PM · America/New_York

Observed Sep 21, 2026, 8:00 PM UTC · Last available price

Johnson & Johnson (JNJ)

Loading market observation…

Research downloads are available with Pro.

Financial Metrics vs. Sector

Upgrade to Plus or Pro to explore this analysis.

Explore plans

Dated financials

As of Sep 22, 2026 · 48 of 48 observations available. Each value retains its reporting period. Trailing 12 months and fiscal-year earnings are separate measures. Financial observations and company disclosures retain their own dates. An observation date is not a filing publication date.

Price and valuation

Closing price was observed on Sep 21, 2026 (as of snapshot date Sep 22, 2026). Financial reporting periods are shown with each observation.

Closing price: 269.47 USD/shares; At Sep 21, 2026; Provider observation · observed Sep 22, 2026
Market capitalization: 649.4B USD; At Sep 21, 2026; Provider observation · observed Sep 22, 2026
P/E · trailing 12 months: 31.15x; Provider TTM · observed Sep 22, 2026
Free cash flow yield: 2.88%; Provider TTM · observed Sep 22, 2026

Compare within the sector

Price to book is particularly useful for financial companies. Price to sales can support comparisons when earnings are negative.

Price to sales: 6.63x; Provider TTM · observed Sep 22, 2026
Price to book: 7.74x; Provider TTM · observed Sep 22, 2026

Additional valuation measures

Fiscal-year P/E uses the last completed financial year. Earnings yield expresses earnings relative to price as a percentage.

P/E · fiscal year: 24.48x; At Sep 18, 2026
Earnings yield: 3.21%; Provider TTM · observed Sep 22, 2026

Financial statements and ratios

Company disclosures

Revenue · quarter: 25.31B USD; At Jun 28, 2026; Provider quarter · observed Sep 21, 2026
Gross profit · quarter: 17.26B USD; At Jun 28, 2026; Provider quarter · observed Sep 21, 2026
Operating income · quarter: 7.17B USD; At Jun 28, 2026; Provider quarter · observed Sep 21, 2026
Net income · quarter: 5.53B USD; At Jun 28, 2026; Provider quarter · observed Sep 21, 2026
Diluted EPS · quarter: 2.27 USD/shares; At Jun 28, 2026; Provider quarter · observed Sep 21, 2026
Operating cash flow · quarter: 4.71B USD; At Jun 28, 2026; Provider quarter · observed Sep 21, 2026
Capital expenditure · quarter: 1.32B USD; At Jun 28, 2026; Provider quarter · observed Sep 21, 2026
Free cash flow · quarter: 3.39B USD; At Jun 28, 2026; Provider quarter · observed Sep 21, 2026

View dated valuation comparison

Research snapshot

Loading research…

Johnson & Johnson research

Loading research…

Model estimates are informational, not investment advice. They are uncertain, may be wrong, and do not guarantee future prices.

Dated financials

Price and valuation

Closing price was observed on Sep 21, 2026 (as of snapshot date Sep 22, 2026). Financial reporting periods are shown with each observation.

Closing price

269.47 USD/shares

At Sep 21, 2026

Provider observation · observed Sep 22, 2026

Market capitalization

649.4B USD

At Sep 21, 2026

Provider observation · observed Sep 22, 2026

P/E · trailing 12 months

31.15x

Provider TTM · observed Sep 22, 2026

Free cash flow yield

2.88%

Provider TTM · observed Sep 22, 2026

Compare within the sector

Price to book is particularly useful for financial companies. Price to sales can support comparisons when earnings are negative.

Price to sales

6.63x

Provider TTM · observed Sep 22, 2026

Price to book

7.74x

Provider TTM · observed Sep 22, 2026

Additional valuation measures

Fiscal-year P/E uses the last completed financial year. Earnings yield expresses earnings relative to price as a percentage.

P/E · fiscal year: 24.48x; At Sep 18, 2026
Earnings yield: 3.21%; Provider TTM · observed Sep 22, 2026

Financial statements and ratios

Company disclosures

Revenue · quarter

25.31B USD

At Jun 28, 2026